This phase II trial is trying to determine how effective a targeted therapy is in the neoadjuvant (pre-) treatment of cutaneous squamous cell carcinoma .
This trial is treating patients with cutaneous squamous cell carcinoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has not spread to other parts of the body.
You may be excluded from this trial if:
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC)
Commercial Sponsor
Regeneron Pharmaceuticals
Summary
Eligible patients will receive intravenous cemiplimab every three weeks.
Recruiting Hospitals Read More